Muckleneuk Pretoria, South Africa
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Phase
3Span
204 weeksSponsor
Alumis IncMarkham, Ontario
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Phase
3Span
101 weeksSponsor
PfizerMarkham, Ontario
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Phase
3Span
157 weeksSponsor
Incyte CorporationMarkham, Ontario
Recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
This study consists of 2 parts: Part A and Part B. Part A: Participants who did not participate in either parent study (TAK-279-3001 [NCT06088043] or TAK-279-3002 [NCT06108544]) may be enrolled and will be treated for up to 52 weeks. Participants who successfully complete Part A of the study are eligible to continue in Part B, but investigators must confirm their eligibility to continue in Part B. Part B: Participants who complete the treatment period of TAK-279-3001 (NCT06088043) or TAK-279-3002 (NCT06108544) parent studies or who complete Part A are eligible to enroll directly into open label extension treatment in Part B and will be treated for up to 156 weeks.
Phase
3Span
88 weeksSponsor
TakedaMarkham, Ontario
Recruiting
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Phase
3Span
148 weeksSponsor
AmgenMarkham, Ontario
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Phase
3Span
249 weeksSponsor
AstraZenecaMarkham, Ontario
Recruiting
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Phase
3Span
101 weeksSponsor
Alumis IncMarkham, Ontario
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects with Non-segmental Vitiligo.
Phase
2Span
87 weeksSponsor
Vyne Therapeutics Inc.Markham, Ontario
Recruiting
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Phase
3Span
159 weeksSponsor
PfizerMarkham, Ontario
Recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.
Phase
3Span
147 weeksSponsor
Celldex TherapeuticsMarkham, Ontario
Recruiting